Building bridges along the psychiatric drug discovery pipeline #5
This the final instalment of a 5-part webinar series between the British Neuroscience Association and the Psychiatry Consortium.
Psychiatric drug discovery must be a truly collaborative process if it is to be successful. All too often industry and academia work exclusively, developing transformative work in isolation of each other and only building alliances at a later stage when necessary. Cross-disciplinary partnerships cultivated earlier in the process can take a project in a whole new direction, for the benefit of those working on the science, for the patient and the investor.
This webinar was originally streamed live via Zoom on Tuesday 22nd March 2022, 1-2pm (GMT) and explored potential solutions to the problem of industry and academia’s sometimes troublesome relationship.
Host organisations: BNA and Psychiatry Consortium Chair: Kevin Cox, (BNA)
Panel of speakers:
• Simon Rose (NHS Foundation Trust)
• Trudi Seneviratne (Royal College of Psychiatrists)
• John Davis (University of Oxford)
• Aslihan Selimbeyoglu (Compass Pathways)